Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The LAST Study: TKI Discontinuation in CML
NCT02269267Phase 2Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Dec 2014
- Primary completion
- Apr 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib, dasatinib, nilotinib, bosutinib in chronic myeloid leukemia (CML), sponsored by Medical College of Wisconsin. Started Dec 2014; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02269267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269267.